SEC Form 4 · accession 0001615774-17-003709
Emmaus Life Sciences, Inc. · EMMA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Donald Eric D'Ambrosio
Officer — Chief Financial Officer
Period of report
Jul 14, 2017
Accepted (ET)
Jul 18, 2017 · 8:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000822370
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to purchase)F1 | $5.90 | Jul 14, 2017 | A | 3,000 | A | Jul 14, 2017 | Mar 31, 2027 | Common Stock | 3,000 | 18,000 | D |
Explanation of responses
- F1In March 2017, the reporting person was granted an option to purchase 18,000 shares of common stock (the "Option Grant"). As previously reported, the Option Grant vests as to 15,000 shares in 36 equal monthly installments from March 31, 2017. Vesting of the Option Grant as to the remaining 3,000 shares was subject to satisfaction by the issuer of a performance condition. The performance condition was met on July 14, 2017, resulting in vesting of the Option Grant as to the remaining 3,000 shares.